PriceTargets.com logo

Surrozen - SRZN Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 13.10%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$33.60 As of 05/1/2026 05:00 PM ET
▲ +0.2 (0.60%)

This chart shows the closing price for SRZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Surrozen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRZN

Analyst Price Target is $38.00
▲ +13.10% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Surrozen in the last 3 months. The average price target is $38.00, with a high forecast of $40.00 and a low forecast of $36.00. The average price target represents a 13.10% upside from the last price of $33.60.

This chart shows the closing price for SRZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Surrozen. This rating has held steady since November 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/3/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/1/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/2/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/21/2026TD CowenInitiated CoverageBuy
3/24/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$40.00
3/24/2026HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $36.00
2/19/2026Cantor FitzgeraldInitiated CoverageOverweight$40.00
2/19/2026Cantor FitzgeraldInitiated CoverageOverweight$40.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/13/2025Lifesci CapitalUpgradeStrong-Buy
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/2/2025HC WainwrightReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
1/30/2025HC WainwrightInitiated CoverageBuy$32.00
1/3/2025GuggenheimUpgradeNeutral ➝ Buy$45.00 ➝ $45.00
11/29/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
11/18/2022GuggenheimDowngradeBuy ➝ Neutral
11/16/2022Bank of AmericaDowngradeNeutral ➝ Underperform
10/17/2022JPMorgan Chase & Co.Initiated CoverageNeutral
5/27/2022Bank of AmericaDowngradeBuy ➝ Neutral
10/11/2021Bank of AmericaInitiated CoverageBuy
9/15/2021GuggenheimInitiated CoverageBuy$300.00
9/7/2021Stifel NicolausInitiated CoverageBuy$285.00
(Data available from 5/3/2021 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2026
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2026

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Surrozen logo
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Read More

Today's Range

Now: $33.60
Low: $32.65
High: $35.00

50 Day Range

MA: $28.15
Low: $25.00
High: $33.40

52 Week Range

Now: $33.60
Low: $5.90
High: $35.00

Volume

62,050 shs

Average Volume

135,276 shs

Market Capitalization

$386.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Surrozen?

The following Wall Street research analysts have issued research reports on Surrozen in the last year: Cantor Fitzgerald, HC Wainwright, Lifesci Capital, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for SRZN.

What is the current price target for Surrozen?

0 Wall Street analysts have set twelve-month price targets for Surrozen in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 13.1%. Cantor Fitzgerald has the highest price target set, predicting SRZN will reach $40.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $36.00 for Surrozen in the next year.
View the latest price targets for SRZN.

What is the current consensus analyst rating for Surrozen?

Surrozen currently has 1 sell rating, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SRZN.

What other companies compete with Surrozen?

Other companies that are similar to Surrozen include Bicara Therapeutics, Precigen, WAVE Life Sciences, MBX Biosciences and Iovance Biotherapeutics. Learn More about companies similar to Surrozen.

How do I contact Surrozen's investor relations team?

Surrozen's physical mailing address is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. The company's listed phone number is 650-489-9000 and its investor relations email address is [email protected]. The official website for Surrozen is www.consonancehfw.com. Learn More about contacing Surrozen investor relations.